|
Balance Sheet Cash Flow Statement 352 Knotter Dr. Cheshire, CT 06410 CT Tel. 203-272-2596 Fax 203-271-8198 |
Type: Public
On the web:
http://www.alexionpharm.com
Employees:
504
Employee growth: 16.1%
Alexion Pharmaceuticals can't suppress its enthusiasm for treating immune functions gone awry. The firm develops drugs that inhibit certain immune system functions that cause autoimmune disorders, cancers, and other diseases. The company's first marketed antibody product, Soliris, has won approval in the US, Canada, and the European Union for the treatment of a rare genetic blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). Alexion is developing the same antibody (eculizumab) used in Soliris as a potential treatment for other autoimmune and inflammatory conditions. The company has additional development programs for cancer-fighting antibodies.
Key numbers for fiscal year ending December, 2008:
Sales: $259.1M
One year growth: 259.7%
Net income: $33.1M
Officers:
Chairman: Max E. Link
CEO, Secretary, Treasurer, and Director: Leonard Bell
VP Site Operations and Engineering: Daniel N. Caron
Competitors:
Abbott Labs
Baxter International
Dyax
